Daily Sepsis Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
Analyzed 32 papers and selected 3 impactful articles.
Selected Articles
1. Transcription Factor GATA3 Ameliorates Sepsis-Associated Acute Respiratory Distress Syndrome by Activating Smad1/5-YAP Pathway via BMP9.
In murine and epithelial cell models of sepsis-associated ARDS, BMP9 overexpression reduced inflammation and ferroptosis by activating Smad1/5–YAP signaling. GATA3 was identified as an upstream transcription factor driving BMP9 expression; inhibiting Smad1/5 or YAP blunted BMP9’s protective effects.
Impact: This study reveals a GATA3–BMP9–Smad1/5–YAP axis that mechanistically limits lung injury in sepsis, nominating actionable molecular targets. It bridges ferroptosis biology with ARDS pathogenesis, offering a coherent therapeutic framework.
Clinical Implications: While preclinical, these data suggest that enhancing BMP9 signaling or modulating GATA3/Smad1/5–YAP could represent new interventions for sepsis-associated ARDS; biomarkers along this axis may aid patient stratification.
Key Findings
- LPS-induced ARDS reduced BMP9, p-Smad1/5, and YAP; BMP9 overexpression reversed these changes and mitigated ferroptosis.
- Pharmacologic inhibition (LDN193189) or knockdown of Smad1/5 or YAP attenuated BMP9’s protective effects.
- GATA3 directly bound the BMP9 promoter, increased transcription, and its knockdown decreased BMP9 and exacerbated injury.
- BMP9 overexpression improved ARDS-related histopathology and inflammatory/oxidative markers in vivo and in vitro.
Methodological Strengths
- Multi-system validation (murine LPS-ARDS model and MLE-12 cells) with convergent phenotypes
- Mechanistic dissection using pharmacologic inhibition, gene knockdown, ChIP-qPCR, and luciferase assays
Limitations
- Preclinical models; lack of human patient validation or clinical biomarkers from ARDS cohorts
- Predominant use of LPS models may not capture full complexity of polymicrobial sepsis
Future Directions: Validate GATA3–BMP9–Smad1/5–YAP biomarkers in human sepsis-associated ARDS, test pharmacologic activators/inhibitors, and assess efficacy in polymicrobial and clinically relevant models.
BMP9 protects against sepsis-induced lung injury. This research aimed to explore how BMP9 affects sepsis-associated acute respiratory distress syndrome (ARDS). Mice and MLE12 cells overexpressing BMP9 were treated with LPS to induce ARDS. Changes in ARDS-related pathological features, ferroptosis, BMP9 expression, and the Smad1/5-YAP pathway were analyzed. Regulation of BMP9 in the Smad1/5 pathway was investigated using the Smad pathway inhibitor LDN193189 and loss-of-function assays. The potential transcription factor of BMP9 was identified using the GEO and ChEA databases and validated through ChIP-qPCR, luciferase reporter assay, and functional experiments. LPS-induced mice exhibited severe lung injury, accompanied by increased inflammation, oxidative stress, and ferroptosis. Furthermore, LPS induction notably decreased BMP9, p-Smad1/5, and YAP levels in mice. BMP9 overexpression alleviated ARDS symptoms and ferroptosis while activating the Smad1/5-YAP pathway. LPS induction reduced cell viability and promoted inflammation, oxidative stress, and ferroptosis in MLE-12 cells, but BMP9 overexpression reversed these changes. Importantly, the protective effects of BMP9 overexpression were weakened by LDN193189 or by Smad1/5 or YAP knockdown. GATA3 was identified as the upstream transcription factor of BMP9, binding upstream of the BMP9 promoter region and activating its transcription. GATA3 knockdown significantly downregulated BMP9 expression in MLE-12 cells. GATA3 expression was notably decreased in ARDS models. In MLE-12 cells overexpressing BMP9, GATA3 knockdown markedly downregulated BMP9, p-Smad1/5, and YAP levels, thereby aggravating ARDS, whereas overexpression of GATA3 exerted protective effects in LPS-treated MLE-12 cells with BMP9 knockdown. In conclusion, GATA3 activates BMP9 transcription, thereby reducing inflammation and ferroptosis in sepsis-associated ARDS via the Smad1/5-YAP pathway.
2. A Systematic Review and Meta-analysis of Externally Validated Epic Clinical Decision Support Tools.
Across 22 external validations (>2.3 million patients), Epic’s models showed modest AUROC and high heterogeneity; the Epic Sepsis Model pooled AUROC was 0.65. Several models underperformed vendor-reported metrics, emphasizing the necessity of local validation and calibration before clinical use.
Impact: This meta-analysis provides the clearest synthesis to date of real-world performance of widely deployed CDS tools, directly informing sepsis screening and deterioration workflows.
Clinical Implications: Health systems should locally validate and calibrate Epic’s sepsis and deterioration models, monitor calibration drift, and integrate model outputs with clinical judgment and early warning systems.
Key Findings
- Epic Sepsis Model pooled AUROC was 0.65 (0.61–0.70) across 3 studies with 922,754 patients.
- Epic Deterioration Index pooled AUROC was 0.79 (0.76–0.80); other models ranged 0.62–0.76.
- High between-study heterogeneity indicates substantial site-level performance variability.
- Several models underperformed relative to vendor-reported ranges, underscoring need for local validation.
Methodological Strengths
- Prospectively registered meta-analysis with multi-database search and random-effects pooling
- Large aggregate sample (>2.3 million) across 34 sites enabling generalizable estimates
Limitations
- Reporting gaps in calibration and thresholds; potential publication bias and variable case definitions
- Heterogeneity limits pooled summary interpretability for local deployment decisions
Future Directions: Standardize reporting (discrimination, calibration, decision-curve), evaluate dynamic recalibration, and test model augmentation with local data for sepsis detection.
BACKGROUND: Clinical Decision Support (CDS) tools integrated with Electronic Health Records increasingly guide clinical practice. Epic Systems, storing more than 325 million patient records, offers various proprietary predictive models to healthcare systems. Despite widespread adoption, no systematic review has examined these tools' real-world performance compared to vendor-reported metrics. METHODS: This study was prospectively registered on PROSPERO (CRD420251148571). We systematically searched PubMed, Scopus, and Embase (January 2018 to August 2025) for external validations of Epic's CDS tools. We pooled Area Under the Receiver Operating Characteristic Curve (AUROC) values using random-effects models and assessed heterogeneity using Higgins' I RESULTS: We included 22 studies in our systematic review, validating Epic CDS tools on a total of over 2.3 million patients and 34 sites. The Epic Deterioration Index (EDI, 7 studies, 542,983 patients) achieved pooled AUROC 0.79 [95% CI 0.76-0.80]; Epic Sepsis Model (ESM, 3 studies, 922,754 patients) 0.65 [0.61-0.70]; Epic Unplanned Readmission Model (EURM, 5 studies, 145,595 patients) 0.70 [0.68-0.73]; Epic End-of-Life Care Index (EEOL-CI, 3 studies, 217,885 patients) 0.76 [0.67-0.83]; and Epic Risk of Patient No-Show (ERPNS, 2 studies, 93,863 patients) 0.62 [0.54-0.68]. All models showed high heterogeneity (I CONCLUSION: Epic's CDS tools demonstrated modest real-world performance, with none exceeding AUROC 0.79. Three models (ESM, EURM, EEOL-CI) underperformed Epic's reported ranges. High heterogeneity across sites emphasizes the need for local validation before clinical deployment.
3. Continuous renal replacement therapy attenuates endothelial injury biomarkers in pediatric sepsis: a prospective cohort study.
In a prospective pediatric cohort, early CRRT was associated with significant longitudinal declines in endothelial injury markers (sICAM-1, sVCAM-1, VEGF, VIM), whereas non-CRRT patients showed no such changes. Higher VEGF, VIM, TM, and t-PAIC were linked to worse outcomes, suggesting surrogate markers for endothelial recovery.
Impact: This is the first prospective pediatric study linking CRRT to endothelial recovery in sepsis, advancing a biomarker framework to evaluate vascular responses to organ support.
Clinical Implications: Monitoring endothelial biomarkers during CRRT may inform therapy timing, intensity, and prognosis in pediatric sepsis; findings warrant randomized trials to test biomarker-guided strategies.
Key Findings
- CRRT group showed significant decreasing trends in sICAM-1, sVCAM-1, VEGF, and VIM over 7 days; non-CRRT showed no clear changes.
- Endothelial biomarkers correlated with albumin and lactate at sepsis diagnosis in the CRRT group.
- Lower VEGF, VIM, TM, and t-PAIC levels were observed in survivors versus non-survivors, indicating prognostic value.
Methodological Strengths
- Prospective design with serial biomarker measurements and mixed-effects modeling
- Comparator group (non-CRRT) allowing temporal contrast in biomarker trajectories
Limitations
- Single-center, non-randomized design with potential confounding by indication
- Sample size not reported; biomarker changes are surrogate endpoints without hard outcomes
Future Directions: Conduct multicenter randomized trials to test CRRT initiation strategies guided by endothelial biomarkers and validate prognostic thresholds.
Endothelial cell (EC) injury is a critical factor in sepsis-induced organ failure. Continuous renal replacement therapy (CRRT) is used to improve hemodynamically unstable sepsis. We conducted a single-center, prospective, observational cohort study to assess whether CRRT attenuates sepsis-associated with EC injury. Based on whether CRRT was implemented within 24 h after admission, patients were divided into non-CRRT and CRRT groups. Demographic data, clinical features, and laboratory indexes were collected, and blood samples were collected at admission, 24 h and 7 days after PICU admission. The levels of vascular endothelial growth factor [VEGF], serum intercellular adhesion molecule-1 [sICAM-1], serum vascular cell adhesion molecule-1 [sVCAM-1], vimentin [VIM]), tissue plasminogen activator-plasminogen activator inhibitor-1 complex [t-PAIC], and thrombomodulin [TM] were not different between the CRRT and non-CRRT groups at PICU admission. The mixed-effects models revealed a significant decreasing trend in EC injury biomarkers (sICAM-1, sVCAM-1, VEGF, and VIM). Nevertheless, there were no obvious changes in these indicators in the non-CRRT group. In the CRRT group, EC injury indicators correlated with albumin and lactic acid at sepsis diagnosis. Serum VEGF, VIM, TM, and t-PAIC levels, but not sVCAM-1 or sICAM-1, were significantly lower in survivors than in non-survivors. Patients with higher serum VEGF, VIM, TM, and t-PAIC levels were at risk of worsening pediatric sepsis outcomes. CRRT downregulated the serum levels of EC injury indicators. This is the first prospective pediatric study linking CRRT to endothelial recovery, and EC biomarkers may serve as surrogate markers for endothelial recovery during CRRT.